Tibsovo led to complete remission in some people with acute myeloid leukemia.

“These are the best outcomes reported to date in a Children’s Oncology Group trial for children with this cancer,” said the lead author.

Moxetumomab pasudotox “offers an option for patients with relapsed or refractory hairy cell leukemia that avoids additional chemotherapy.”

Tom and Kari Whitehead share how their daughter’s experience with CAR-T therapy motivated them to support research.

Oncologists are excited about the increased options available to patients, and about the promise of even more new therapies to come.

“When your doctor says the No. 1 pediatric stem cell transplant hospital in the world is 90 minutes from your house, you don’t question it...

The link between the older interferon treatment and these cancers may be related to the drug’s low hep C cure rate.

Aside from taking antiretrovirals, quitting smoking is the number one way people with HIV can lower their risk of illness and death.

Approval extended to people who are in remission but have minimal residual disease.